BOD (ASX:BOD) shares gain attention on quarterly update

Image Source: © Miluxian |


  • BOD Australia has made solid progress towards the commencement of clinical trials and product commercialisation.
  • Cannabis sales increased by 2% from the previous quarter.
  • The company secured Clinical Trial Authorisation from the UK’s Medicines & Healthcare Products Regulatory Agency.


The shares of cannabis-focused drug development and product innovation company Bod Australia Limited (ASX:BOD) are gaining attention following its Q3 FY2022 update.

BOD shares traded flat at AU$0.170 per share at 3:36 PM AEST today.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and